Abstract 76P
Background
The study is aimed to identify perception and satisfaction of cancer patients who participate in clinical trials.
Methods
The participants of the study were 110 cancer patients who participated in clinical trials over 2nd cycle at a tertiary hospital, Seoul, South Korea. The instruments used were the perception and satisfaction of cancer patients in clinical trials developed after evaluating content validity index. The collected data were analyzed with descriptive statistics, independent t-test, one-way ANOVA and Pearson Correlation Coefficients.
Results
The mean perception of clinical trial of patients was 3.97±0.46 out of 5.0. The mean satisfaction of clinical trial of patients was 4.10±0.55 out of 5.0. The perception of cancer patients in clinical trials was significantly difference according to types of cancers (F = 2.88, p=.018), participation period (F = 3.13, p=.029) and subjective understanding of the clinical trial (t = 2.65, p=.015). Satisfaction of cancer patients showed significant difference according to religion (t = 2.32, p=.023), participation period (F = 3.39, p=.021), motive to participate (F = 3.18, p=.010) and decision maker of participation (t = 2.60, p =.025). Perception and satisfaction of cancer patients in clinical trials were positively correlated (r=.66, p<.001).
Conclusions
The results of study can be used as a basis for education program for cancer patients participating in clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract